Actively Recruiting
Study Evaluating VV-14303 Gene Therapy for Adults With Metabolic Dysfunction-associated Steatohepatitis MASH Using Dose Escalation to Assess Safety and Efficacy
Led by Kriya Therapeutics, Inc. · Updated on 2026-09-01
56
Participants Needed
3
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating VV-14303, a gene therapy using an adeno-associated virus vector to deliver Fibroblast Growth Factor 21 FGF21, for adults with Metabolic Dysfunction-associated Steatohepatitis MASH. This Phase 12 study aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of VV-14303 in this condition. The trial is a first-in-human, multi-arm, dose-escalation study conducted by Kriya Therapeutics, Inc.
CONDITIONS
Brief Title
A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)
Research Team
V
VP, Medical Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here